Account
Articles
01.03.2022
China's most recent NRDL update

In December 2021, China once again updated its National Reimbursed Drugs List (NRDL).

Read more
Articles
24.02.2022
Patient reported outcomes

This educational blog explores what PROs are, explains why they of growing importance in the digital...

Read more
Articles
07.02.2022
Advanced therapy medicinal product withdrawals

Advanced therapy medicinal products (ATMPs) are medicinal products for human use that are based on l...

Read more
Articles
02.02.2022
Developing a STA/HST submission to NICE

NICE require a broad range of evidence to be included within the reimbursement dossier, including cl...

Read more
Articles
01.02.2022
Changes to NICE's health technology evaluation

This reforms have been welcomed by the industry as they should support faster access to medicines as...

Read more
Articles
27.01.2022
Early access schemes in France

The 2021 Social Security Law made provision for overhauling the early scheme in France. As of 1st Ju...

Read more
Articles
25.01.2022
PMA Perspectives Q1 2022

We hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth ...

Read more
Articles
20.01.2022
Orphan drugs market access

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo a r...

Read more
Articles
17.01.2022
COVID-19 Two Year Review

As we enter 2022, we are approaching the two-year anniversary of the COVID-19 pandemic spreading acr...

Read more
Articles
10.01.2022
Conducting a HTA review

Reviewing previous HTA submissions can provide valuable insights that can help manufacturers prepare...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.